Literature DB >> 22878163

Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.

Reisa A Sperling1, Keith A Johnson, P Murali Doraiswamy, Eric M Reiman, Adam S Fleisher, Marwan N Sabbagh, Carl H Sadowsky, Alan Carpenter, Mat D Davis, Ming Lu, Matthew Flitter, Abhinay D Joshi, Christopher M Clark, Michael Grundman, Mark A Mintun, Daniel M Skovronsky, Michael J Pontecorvo.   

Abstract

The objective of this study was to evaluate the relationship of amyloid burden, as assessed by florbetapir F 18 ((18)F-AV-45) amyloid positron emission tomography, and cognition in healthy older control (HC) subjects. Seventy-eight HC subjects were assessed with a brief cognitive test battery and positron emission tomography (PET) imaging with (18)F-AV-45. A standard uptake value ratio was computed for mean data from 6 cortical regions using a whole cerebellum reference region. Scans were also visually rated as amyloid positive or amyloid negative by 3 readers. Higher standard uptake value ratio correlated with lower immediate memory (r = -0.33; p = 0.003) and delayed recall scores (r = -0.25; p = 0.027). Performance on immediate recall was also lower in the visually rated amyloid positive compared with amyloid negative HC (p = 0.04), with a similar trend observed in delayed recall (p = 0.06). These findings support the hypothesis that higher amyloid burden is associated with lower memory performance among clinically normal older subjects. Longitudinal follow-up is ongoing to determine whether (18)F-AV-45 may also predict subsequent cognitive decline.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878163      PMCID: PMC3518678          DOI: 10.1016/j.neurobiolaging.2012.06.014

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  47 in total

1.  Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data.

Authors:  Andrei G Vlassenko; Mark A Mintun; Chengjie Xiong; Yvette I Sheline; Alison M Goate; Tammie L S Benzinger; John C Morris
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

4.  Face-name associative memory performance is related to amyloid burden in normal elderly.

Authors:  Dorene M Rentz; Rebecca E Amariglio; J Alex Becker; Meghan Frey; Lauren E Olson; Katherine Frishe; Jeremy Carmasin; Jacqueline E Maye; Keith A Johnson; Reisa A Sperling
Journal:  Neuropsychologia       Date:  2011-06-12       Impact factor: 3.139

5.  Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Authors:  Gaël Chételat; Victor L Villemagne; Kerryn E Pike; Kathryn A Ellis; Pierrick Bourgeat; Gareth Jones; Graeme J O'Keefe; Olivier Salvado; Cassandra Szoeke; Ralph N Martins; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2011-02-09       Impact factor: 13.501

6.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

7.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

8.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Amyloid deposition is associated with impaired default network function in older persons without dementia.

Authors:  Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson
Journal:  Neuron       Date:  2009-07-30       Impact factor: 17.173

10.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

View more
  62 in total

1.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

2.  Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2017-04-12       Impact factor: 2.035

3.  White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients.

Authors:  Yongxia Zhou; Fang Yu; Timothy Q Duong
Journal:  J Magn Reson Imaging       Date:  2013-12-31       Impact factor: 4.813

4.  Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.

Authors:  Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis.

Authors:  S Duke Han; Caroline P Nguyen; Nikki H Stricker; Daniel A Nation
Journal:  Neuropsychol Rev       Date:  2017-05-11       Impact factor: 7.444

6.  Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.

Authors:  Kelly R Murphy; Susan M Landau; Kingshuk Roy Choudhury; Christopher A Hostage; Katie S Shpanskaya; Haris I Sair; Jeffrey R Petrella; Terence Z Wong; P Murali Doraiswamy
Journal:  Neuroimage       Date:  2013-04-23       Impact factor: 6.556

7.  Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.

Authors:  Andrew J Aschenbrenner; David A Balota; Chi-Shing Tse; Anne M Fagan; David M Holtzman; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2014-09-15       Impact factor: 3.295

Review 8.  Molecular imaging of Alzheimer disease pathology.

Authors:  K Kantarci
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-06       Impact factor: 3.825

Review 9.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

10.  Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.

Authors:  Adam P Mecca; Nicole M Barcelos; Shuo Wang; Anna Brück; Nabeel Nabulsi; Beata Planeta-Wilson; Jennifer Nadelmann; Amanda L Benincasa; Jim Ropchan; Yiyun Huang; Joel Gelernter; Peter H Van Ness; Richard E Carson; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2017-10-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.